Last updated on April 17, 2014 at 17:30 EDT

Cardiome Pharma Corp. Announces Voting Results

July 2, 2013


VANCOUVER, July 2, 2013 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced the results of voting at its 2013 Annual
General and Special Meeting of Shareholders held on June 28, 2013.

A total of 7,995,664 common shares were voted in connection with the
meeting, representing approximately 64.12% of the issued and
outstanding common shares of the company. Shareholders voted as

Appointment of Auditor

By resolution passed by show of hands, KMPG LLP, Chartered Accountants,
was appointed auditor of the company for the ensuing year.

Election of Directors

By resolution passed by ballot vote, the following five nominees
proposed by management were elected as directors of Cardiome to hold
office until the next annual meeting of Shareholders or until their
successors are elected or appointed:

    |Nominee   |Votes For|% Votes For|Votes Withheld|% Votes Withheld|
    |Robert W. |4,859,925|    99.18  |      40,088  |         0.82   |
    |Rieder    |         |           |              |                |
    |Peter W.  |4,857,052|    99.12  |      42,961  |         0.88   |
    |Roberts   |         |           |              |                |
    |Harold H. |4,813,131|    98.23  |      86,882  |         1.77   |
    |Shlevin   |         |           |              |                |
    |Richard M.|4,856,952|    99.12  |      43,061  |         0.88   |
    |Glickman  |         |           |              |                |
    |William L.|4,860,562|    99.19  |      39,451  |         0.81   |
    |Hunter    |         |           |              |                |

Renewal of Stock Option Plan

By resolution passed by show of hands, the Cardiome’s Stock Option Plan
was ratified, confirmed and re-approved, all unallocated options under
the Stock Option Plan were approved, and the Company was granted the
ability to continue granting options under the Stock Option Plan until
June 28, 2016.

Adoption of Advance Notice Bylaw

By resolution passed by show of hands, an amendment to the company’s
by-laws was approved to adopt provisions regarding advanced notice for
director nominations (the “Advance Notice Bylaw”) as outlined in the
company’s management information circular.

The purpose of the Advance Notice Bylaw is to provide shareholders,
directors and management of Cardiome with direction on the procedure
for shareholder nomination of directors.  The Advance Notice Bylaw is
the framework by which the company seeks to fix a deadline by which
registered or beneficial holders of common shares of the company must
submit director nominations to the company prior to any annual or
special meeting of shareholders and sets forth the information that a
shareholder must include in the notice to the company for the notice to
be in proper written form. No person will be eligible for election as a
director of the company unless nominated in accordance with the
provisions of the Advance Notice Bylaw.

In the case of an annual meeting of shareholders, notice to the company
must be made not less than 30 days and not more than 60 days prior to
the date of the annual meeting; provided, however, that in the event
that the annual meeting is to be held on a date that is less than 60
days after the date on which the first public announcement of the date
of the annual meeting was made, notice may be made not later than the
close of business on the 10th day following such public announcement.

In the case of a special meeting of shareholders (which is not also an
annual meeting), notice to the company must be made not later than the
close of business on the 10th day following the day on which the first
public announcement of the date of the special meeting was made.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one
marketed product, BRINAVESS(TM) (vernakalant IV), approved in Europe and
other territories for the rapid conversion of recent onset atrial
fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto
Stock Exchange (COM). For more information, please visit our web site
at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions.  Forward- looking
statements may involve, but are not limited to, comments with respect
to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research and development and product and drug development. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada, Europe, and the other regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and
changes in, or the failure to comply with, governmental legislation and
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical and
clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products; decisions, and the
timing of decisions, made by health regulatory agencies regarding
approval of our technology and products; the requirement for
substantial funding to expand commercialization activities; and any
other factors that may affect our performance. In addition, our
business is subject to certain operating risks that may cause any
results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and
clinical development of our products; changes in our business strategy
or development plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from
third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to finance
our activities; and any other factors described in detail in our
filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to
place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein
are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.

Source: PR Newswire